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ABSTRACT
In this project, an evidential reasoning model is built to amalgamate factors that could be used in
early detection of pancreatic cancer. Our machine learning model outputs a probability of a given
patient having prostate cancer based on various input variables. These variables include health
history factors, such as smoking and medical history, technical artifacts, such as biopsy
sequencing technology, and genomic biomarkers such as mutational, transcriptional and
methylomic profiles, cfDNA, and copy number variation. The dataset used in this project is a
part of The Cancer Genome Atlas (TCGA) project and was collected from the National Cancer
Institute (NIH) Genomic Data Commons (GDC). The model is tested by varying input
propositions and probability mass functions of input frames to create different combinations of
input factors. Baseline prediction results in (0.084, 0.19) of not having pancreatic cancer.
Prediction results were compared to the baseline prediction and a set of positive control
expectations. For example, medium to high smoking history, medium to high drinking history
with some cancer history will increase the posterior belief of a patient having pancreatic cancer
to (0.091, 0.208). Presence of prognostic biomarkers will also increase the support for having
pancreatic cancer, having medium impact DNA methylation and medium impact mRNA
expression can lead the belief of having pancreatic cancer increase to (0.167, 0.273).
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THE USE OF EVIDENTIAL REASONING MODEL WITH BIOMARKERS IN PANCREATIC CANCER PREDICTION

I. INTRODUCTION
Pancreatic cancer is the result of uncontrolled division of malignant cells in the pancreas.
With its late and few symptoms, pancreatic cancer is ranked as the fourth leading cause of
cancer-related mortality worldwide [1]. The death toll recorded in 2015 from pancreatic cancer
alone, among all the different types of cancer, was 411,600 deaths globally [2]. In the United
States, it is the third-most-common cause of death [3]. It is more prevalent within the developed
countries, accounting for about 70% of new cases recorded in 2012 [4].
It is quite a rare occurrence for patients below the ages of 40 to be diagnosed with this
disease condition, while more than half of patients diagnosed with pancreatic adenocarcinoma
are over 70 [5]. Risk factors associated with it are some rare genetic predisposition conditions,
tobacco smoking, obesity and diabetes.
Although expressed in various types, pancreatic cancer can be categorized into two
groups, the exocrine and endocrine groups.
● Exocrine group: This group accounts for the vast majority of pancreatic cancer cases
and occurs within the part of the pancreas responsible for digestive enzyme production,
called the exocrine component. And among all types within this group, pancreatic ductal
adenocarcinoma (PDAC) constitute over 90%, making it by far the most common type of
pancreatic cancer cases [1]. This is quite the case despite the fact that the tissue it arises
from constitutes only 10% of the pancreas cell volume, because it is just the duct within
the pancreas [6]. The next most common type, representing about 5% of the exocrine
group of cancers is called the acinar cell carcinoma[7]. Accounting for 1% of pancreatic
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cancer cases is another type known as Cystadenocarcinomas [7]. Compared to other types
of exocrine cancers, it has a better prognosis.
● Endocrine group: As for the second group, endocrine group of cancers, they account for
the small minority types of cancer and are also called pancreatic neuroendocrine tumors
(PanNet) [8]. These diverse groups of sometimes benign tumors arise from the body's
neuroendocrine cells, which serves to integrate the endocrine and nervous systems. There
are two types of endocrine group of cancers, the functioning and nonfunctioning types.
The difference between both is the amount of hormones they secret. Functioning types,
secret hormones in large quantities that often results in serious symptoms, favoring early
detection. As for the second type, nonfunctioning PanNet, because they do not secrete
hormones in sufficient quantities, it doesn't result in overt clinical symptoms and
therefore are only diagnosed after it has spread to other body organs [8].

The prognosis for pancreatic adenocarcinoma is very poor, as 25% survive one year after
diagnosis and 5% live for five years; if detected early, it increases to 20% [4][9]. As for
neuroendocrine types of cancer, they've got a better survival rate, of which after five years of
diagnosis, 65% are living depending on the type of tumor [4]. Aside from the fact that the
symptoms of PDAC do not usually appear at an early stage, they are not individually distinctive.
Symptoms vary according to the cancer's location in the pancreas. While tumors in the body and
tail of the pancreas express painful symptoms, those at the head typically cause dark urine,
jaundice, loss of appetite and so on.

2

THE USE OF EVIDENTIAL REASONING MODEL WITH BIOMARKERS IN PANCREATIC CANCER PREDICTION

To confirm diagnosis and its resectability, medical imaging techniques such as
endoscopic ultrasound and computed tomography (CT scan) are employed. Abdominal
ultrasound tends to miss small tumors but is effective in identifying cancers that have spread to
the liver [10]. Pancreatic cancer is tackled using radiotherapy, chemotherapy, palliative care and
undergoing surgery.

II. BACKGROUND
Pancreatic cancer has such an alarming death rate because about 80-85% of patients are
diagnosed when the disease has gotten to its late stage, and often already spread to other organs
[11]. At such a stage, curative surgical resection is not possible. However, it takes a period of
one or two decades between chronic pancreatitis diagnosis and an overt tumor [12]. Capitalizing
on this long latency period will really curb the mortality rate when diagnosed early and treatment
is commenced.
A. Detection with Biomarker
Compared to other tumors, such as those for lungs, breast, cervix and colon, the screening
program for PDAC remains a challenge. Barrier hindering its progress includes the specificity of
the test. This has led to lots of false cases because it requires a high performing screening test
that's having a very high sensitivity. As a result of this, there has been an ongoing intensive effort
aimed at discovering pancreatic cancer-associated biomarkers meant to assist in early detection,
diagnosis and predicting response to treatment. These efforts have focused on serum biomarkers.
A biomarker is any substance, molecule that is measured in the body and that can be used
to predict the incidence or outcome of a disease. The absence of reliable biomarkers to capture
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the early development of this disease, oftentimes, has resulted in patients being diagnosed when
it's at an advanced or critical stage. So far, the US Food and Drug Administration (FDA) has
approved only one biomarker associated with pancreatic cancer treatment, serum
protein-carbohydrate antigen 19-9 (CA19-9 or sialylated Lewis antigen).
Unfortunately, CA19-9 has not really been effective for early detection due to its low
specificity and sensitivity. With a sensitivity of 79-81% and a specificity of 82-90%, it has a poor
predictive value in asymptomatic patients [13]. Not only that other types of cancer can lead to
elevated CA19-9 levels but about 10% of the Caucasian population lacks CA19-9 on their red
blood cells [14]. Therefore, up to date, there's no reliable biomarker approved for early diagnosis
of pancreatic cancer in clinical settings.
Another vital role biomarkers play is that they can be used to monitor treatment efficacy
and any resurgence of resected tumors. In fact, this is the function CA 19-9 currently serves, as
they're used to provide valuable information regarding the patient's response to pancreatic cancer
treatment. After the patient has been diagnosed of having pancreatic cancer, the healthcare team
takes a baseline (initial) measurement of CA 19-9. As the patient commences treatment, the CA
19-9 levels are continuously measured till completion of treatment. The changes recorded in
these levels enable the doctors to ascertain if the tumor is growing, diminishing or staying the
same size.
Another biomarker that’s often under investigation is known as KRAS mutations, which
occur in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene. Although these occur
frequently in pancreatic cancer, its diagnostic accuracy is not sufficient enough for clinical
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utilization. This is the result of non-specificity of KRAS mutations as they are observed in many
tumor types. From the extensive studies carried out, low levels of cell-free circulating DNA in
serum were observed, thereby limiting the use of non-invasive assays for clinical diagnostics
[15]. Other biomarkers under investigation include various microRNAs, Macrophage inhibitory
cytokine 1 (MIC1), Peptidylglycine Alpha-Amidating Monooxygenase (PAM 4), Glypican
(GPCX), Osteopontin (SPP1), DNA methylation and RNA transcriptional profiles, copy number
variation information, and signaling pathway-level aberrations.
B. Sequencing
Advances in DNA and RNA sequencing technologies provided scientists and clinicians
with ability to understand the molecular differences between normal and malignant tissues.
Sequencing is the method of determining the sequence

arrangement of DNA or RNA

nucleotides. Different sequencing strategies have assisted with revealing new transformations
tumor cells.
Next-generation sequencing technology (NGS) has brought many important discoveries
to cancer research and treatment. Finding the tumor driver genes and related signal transduction
pathways has become a new strategy for current clinical tumor assessment and treatment. For
example, study [16] includes a total of 22 patients with pancreatic cancer and 42 genes and 61
loci were detected by NGS to have DNA mutations. The mutation rate of TP53, KRAS,
CDKN2A, SMAD4 genes is significantly higher than other genes. Researchers in [17] extract
DNA from plasma samples and use NGS analysis methods to detect allelic mutation frequencies.
The three most common KRAS mutations in blood samples of pancreatic cancer were screened
by droplet digital PCR (dPCR). Through multivariate analysis, it is revealed that ctDNA in the
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blood is a prognostic biomarker for patients with pancreatic cancer and is related to the
development of the disease and the degree of tumor differentiation. As the tumor progresses, it
sheds some of its DNA into the bloodstream. Blood-based assays can be utilized to detect DNA
that came from malignant cells in pancreas.
Advances in next-generation sequencing technologies also promote the development of
whole-genome-sequencing (WGS) and whole-exome-sequencing (WES). While WES is capable
of detecting mutations in the tumor exome, WGS can be used to detect all somatic mutations in
tumor samples.
C. Machine Learning
Massive cancer data has been generated as recent advances have taken place in the field of
medicine. However, predicting an outcome correctly still remains challenging and fascinating for
doctors and biomedical researchers. This has made Machine Learning (ML) methods an
informative tool for medical sciences. ML techniques can model trends and associations from
diverse data sets while accurately predicting diagnostic, therapeutic, and prognostic outcomes for
each specific cancer type.
Prognosis and prediction of diseases with various techniques and feature selection
algorithms have widely applied in the last two decades [18]. Most of these initiatives use ML
approaches to model cancer development and detect useful factors subsequently used in ML
classifications. These methods use clinical, histological, and genomic data to model
tumorigenesis. For almost three decades, leading ML techniques like Artificial Neural Networks
(ANNs) and Decision Trees (DT) were used in cancer detection. Based on the investigation done
by [19], more than 7,510 papers have been published to date on the topic of ML and cancer.
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Most publications use ML algorithms and incorporate heterogeneous tumor detection data and
cancer prediction/forecast data. In the past decade, a trend has developed towards cancer
detection and prediction, and other controlled teaching techniques have been noted. All these
classification algorithms have been used across cancer types.
D. Research on evidential reasoning
When multimillion-dollar decisions are about to be made, hinging such decisions on
results obtained from traditional decision-analytic and probabilistic approaches is quite risky.
This is because, in practice, the true probability distribution of all factors might never be known
even if the requirements and assumptions the calculus requires are known. For better decision
making, the evidential-based approach was developed, with the works of Arthur Dempster and
Glenn Shafer serving as its basis [20]. The term "evidence" denotes that data are best treated
such that they either tend to support or refute to varying degrees probabilistic arguments of
different alternatives. Unlike traditional probabilistic techniques that require point estimations,
this technique makes use of interval estimations. A great advantage is that the prior data required
is more intuitive and easy to obtain.
This project is an extension of former projects completed by Chandratre, and Sharghi
[21][22]. The genomic dataset used in their studies are taken from the National Cancer Institute
(NIH) Genomic Data Commons (GDC). Not only the outcome of the machine learning model
with Support Vector Classifier (SVC) is used, their evidential reasoning (ER) model also takes
other factors that may affect the predictions. For example, NGS technology used and sequencing
reads could affect the outcome of machine learning prediction. The list of all inputs of their ER
model is: NGS technology, sequence read, smoking history, drinking history, family medical
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history, patient medical history, biopsy site cell result, and amount of genetic material.
Experiments done by adjusting the proposition and mass of input frames is consistent with
intuitive judgement of the prediction [21][22].
Chandratre built on Sharghi’s project by creating an improved version of machine
learning classifier by taking all projects in the NIH GDC portal into account. This includes
22,872 genes and 3,142,246 total mutations related to these genes [22]. The improved model also
considered the lethality of mutations, the impact of each mutation on the mutated protein can be
classified as VEP, SIFT, and PolyPhen in NIH GDC portal. Sharghi’s model reported a high
SVC prediction accuracy of ~91%, but only used gene-mutation combinations occurred in 185
cases of the TCGA-PAAD dataset. Result of the improved model shows a low prediction
accuracy ~85% with small standard deviation by considering VEP impact [22].
E. Remaining technical gaps
Current diagnostic approaches of detecting pancreatic cancer neglect to analyze the
pancreatic disease in its early phase, bringing about a reduction in this current condition's
survival rate. In addition, in the case of a fatal disease like pancreatic cancer, it has been proven
unreliable and imprecise to count on the limited resources available for analysis, including the
Artificial Intelligence (AI)-assisted genomic data analysis and the few biomarkers known to be
causative.
The reasoning for this is that several variables contribute to the cell mutation in pancreas.
These reasons might be personal habits (dietary habits, use of cigarettes, liquor intake, and so
forth) or even inherited (hereditary conditions caused by certain germline genetic mutations). All
these factors along with the available analytical data can be ambiguous, inconsistent, uncertain,
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or even deficient. In correlation, if data regarding age and race of higher-risk people were to be
considered, maybe only a certain group of the larger population will be ultimately diagnosed
[21].
To maximize the chance of correctly prognosis of pancreatic cancer, all different factors
that could contribute to cancer development should be taken into consideration. Evidential
reasoning model and the Belief Function (BF) thus become a crucial part to formulate rational
and sound conclusions in relation to the probability of developing pancreatic cancer. This is
accomplished more straightforwardly and less confining than standard analytical and
probabilistic strategies [20].

III. APPROACH
With a considerable development of research suggesting the presence of change of
certain genetic material may lead to malignant tumors in their pancreas. This project tries to
bring the gap in pancreatic cancer research to make predictions based not only on environmental
factors, and factors that can affect machine learning outcome, but also try to incorporate
biomarkers in addition to the work done by Chandratre and Sharghi.
The biomarkers used in this project are namely: novel/rare mutation, pathway mutation,
DNA methylation, cfDNA/cfDNA methylation, mRNA expression, exosome-miRNA,
circulating tumor cell (CTC), and copy number variation (CNV). (Check Appendix C to J for
more information regarding each biomarker).
Each biomarker is used as an input frame in the project, frames are mutually exclusive
random variables. The collection of frames is called a galley. This project contains a galley file
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that records information for each frame: frame name, frame type, propositions, input node,
output node, and compatrel relationship between frames. Proposition is a value of the frame, the
set of propositions in a frame is mutually exclusive and exhaustive in the BF world. Frame type
indicates if the propositions are discrete or continuous. For example, the outcome of a machine
learning prediction can be PC or NOT_PC, they are discrete propositions of ML_PREDICTION
frame. For each frame, a probability value representing a degree of belief denoted as “mass” is
assigned to the subset of propositions of the frame. The baseline proposition and mass can be
found in Appendix A Table I. For example, the baseline mass 0.5 is assigned to LOW_IMPACT
proposition of the DNA methylation frame, it represents there’s 0.5 confidence from the
evidence that supports DNA methylation frame has low impact. The remaining mass of 0.5
means DNA methylation could be either LOW_IMPACT, MEDIUM_IMPACT, or
HIGH_IMPACT. In another case, cfDNA/cfDNA methylation frame has a vacuous mass of 1.0
assigned to the proposition set (LOW_IMPACT, MEDIUM_IMPACT, HIGH_IMPACT), which
means that mass 1.0 is assigned to a disjunction of of the set of all propositions in the frame.
Although there are many studies on biomarker, the current researches show different
degrees of understanding of the role of each biomarker in pancreatic cancer prediction. A
discount value is assigned to each frame to decrease the impact of conviction for the
predisposition of this frame to pancreatic cancer. For example, CNV is assigned a higher
discount rate, because research papers like [23] mention that the correlation between CNV and
pancreatic cancer need to be elucidated by further investigation. Compared to NGS technology
which provides concrete data, smoking history or drinking history has a higher discount rate,
because they could be inaccurate and subjective. The value of discount rate is selected based on

10

THE USE OF EVIDENTIAL REASONING MODEL WITH BIOMARKERS IN PANCREATIC CANCER PREDICTION

subjective estimation. When a discount rate of 0.7 is applied, only 70% of the mass will be used
in the calculation.
The evidential model sets up the conviction of predicting pancreatic malignancy relying
upon the combination of propositions and their masses as inputs. Frames are combined based on
Dempster’s rule of combination. Some frames map directly to calculating the chance of having
pancreatic cancer, while a disjunction of related frames can also form intermediate nodes. These
intermediate nodes aggregate the evidence provided by the input nodes. For example, an
intermediate node is created using BIOPSY_SITE_CELL_RESULT and
AMOUNT_GEN_MATERIAL as direct input nodes, since the different amount of material
taken at a biopsy site may affect sequencing and ML outcome. There’s also an intermediate node
created between SMOKING_HISTORY, DRINKING_HISTORY, FAMILY_MED_HISTORY,
and PATIENT_MED_HISTORY, because as [24] has shown, there is a high co-occurrence
between smoking and drinking behaviors, and smoking and drinking habits will tend to result in
medical conditions. Figure 1 and Figure 2 shows all the input frames and intermediate nodes for
this project.
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Figure 1. Evidential Reasoning Model (left)
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Figure 2. Evidential Reasoning Model (right)
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IV. EXPERIMENTS
Our evidential reasoning model is tested by adjusting the proposition and mass of the
input frames to see if the prediction is expected. The ER prediction using all frames with
baseline inputs mass, proposition, and discount rate gives the following output:
Belief Of Having Pancreatic Cancer Lies Between: (0.084, 0.19) (0)|**--------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.809, 0.915) (0)|--------**|(1)
The following experiments aim to demonstrate how adjusting input factors affect the final
prediction. A updating program is used to update the mass and propositions for input frames,
information about how the program is used can be found in Appendix K.

A. ER Experiment 1
Since there’s an intermediate node created for BIOPSY_SITE_CELL_RESULT and
AMOUNT_GEN_MATERIAL. This experiment aims to demonstrate how change in biopsy
sites, and the amount of genetic material taken from the biopsy site affects the result of the
prediction. Adjust the two frames and keep the values of all other input parameters the same as
the baseline values. The prediction results are shown in the following table:
Biopsy site
Proposition

Amount of genetic
material
Mass

Proposition

Mass

Belief Of Having
Pancreatic Cancer
Lies Between:

Belief Of Not
Having Pancreatic
Cancer Lies
Between:

NEAR_PAN_
IRREG

0.7

SMALL

0.7

(0.09, 0.205)
(0)|***-------|(1)

(0.794, 0.909)
(0)|-------***|(1)

NEAR_PAN_
IRREG

0.3

MEDIUM

0.3

(0.116, 0.226)
(0)|-**-------|(1)

(0.773, 0.883)
(0)|-------**-|(1)

NEAR_PAN_
IRREG

0.7

MEDIUM

0.7

(0.29, 0.381)
(0)|--**------|(1)

(0.619, 0.709)
(0)|------**--|(1)
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NEAR_PAN_
IRREG

0.7

HIGH

0.7

(0.291, 0.381)
(0)|--**------|(1)

(0.619, 0.708)
(0)|------**--|(1)

NOT_NEAR_ 0.7
PAN_IRREG

SMALL

0.7

(0.09, 0.202)
(0)|***-------|(1)

(0.797, 0.909)
(0)|-------***|(1)

NOT_NEAR_ 0.7
PAN_IRREG

LARGE

0.7

(0.089, 0.202)
(0)|***-------|(1)

(0.797, 0.91)
(0)|-------***|(1)

NEAR_PAN_
REG

0.7

SMALL

0.7

(0.039, 0.09)
(0)|*---------|(1)

(0.909, 0.96)
(0)|---------*|(1)

NEAR_PAN_
REG

0.7

LARGE

0.7

(0.09, 0.204)
(0)|***-------|(1)

(0.795, 0.909)
(0)|-------***|(1)

NOT_NEAR_ 0.7
PAN_REG

SMALL

0.7

(0.016, 0.04)
(0)|*---------|(1)

(0.96, 0.983)
(0)|---------*|(1)

NOT_NEAR_ 0.7
PAN_REG

LARGE

0.7

(0.09, 0.202)
(0)|***-------|(1)

(0.797, 0.909)
(0)|-------***|(1)

Table 1. Prediction result of various input parameters for biopsy site and amount of material
From the table above we can see that when the biopsy site is NEAR_PAN_IRREG,
NEAR_PAN_REG, or NOT_NEAR_PAN_REG, change the amount of genetic material from
SMALL to MEDIUM or HIGH, will lead to an increase in the belief of having pancreatic cancer.
When the biopsy site is NOT_NEAR_PAN_IRREG with mass 0.7, change the amount of
material from SMALL to LARGE, the prediction doesn’t change. When the biopsy site is
NEAR_PAN_IRREG with MEDIUM amount of genetic material, increasing the mass from 0.3
to 0.7 also leads to an increase in the belief of having pancreatic cancer.

B. ER Experiment 2
An intermediate node is created between SMOKING_HISTORY,
DRINKING_HISTORY, FAMILY_MED_HISTORY, and PATIENT_MED_HISTORY. This
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experiment tests how varying mass distribution and proposition affects the result of prediction.
Adjust the four frames and keep the values of all other input parameters the same as the baseline
values. The prediction results are shown in the following table:
Smoking history

Drinking history

Family med. history

Patient med. history

Proposition

Proposition

Proposition

Proposition

LOW

Mass
0.3

LOW

Mass
0.3

NO_CANC
ER

Mass
0.3

NO_CAN
CER

Mass
0.3

Belief Of Having Pancreatic Cancer Lies Between: (0.092, 0.207)(0)|***-------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.792, 0.907)(0)|-------***|(1)
LOW

0.7

LOW

0.7

NO_CANC
ER

0.7

NO_CAN
CER

0.7

Belief Of Having Pancreatic Cancer Lies Between: (0.085, 0.191)(0)|**--------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.808, 0.914)(0)|--------**|(1)
LOW

0.7

LOW

0.7

SOME_CA
NCER

0.7

SOME_C
ANCER

0.7

Belief Of Having Pancreatic Cancer Lies Between: (0.092, 0.207)(0)|***-------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.792, 0.907)(0)|-------***|(1)
MEDIUM

0.3

MEDIUM

0.3

SOME_CA
NCER

0.3

SOME_C
ANCER

0.3

Belief Of Having Pancreatic Cancer Lies Between: (0.091, 0.208)(0)|***-------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.791, 0.908)(0)|-------***|(1)
MEDIUM

0.7

MEDIUM

0.7

SOME_CA
NCER

0.7

SOME_C
ANCER

0.77

Belief Of Having Pancreatic Cancer Lies Between: (0.092, 0.208)(0)|***-------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.791, 0.907)(0)|-------***|(1)
HIGH

0.3

HIGH

0.3

CANCER

0.3

CANCER

0.3

Belief Of Having Pancreatic Cancer Lies Between: (0.092, 0.207)(0)|***-------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.792, 0.907)(0)|-------***|(1)
HIGH

0.7

HIGH

0.7

CANCER
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Belief Of Having Pancreatic Cancer Lies Between: (0.109, 0.223)(0)|-**-------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.776, 0.89)(0)|-------**-|(1)
Table 2. Prediction result of various input parameters for smoking history, drinking history,
family medical history, and patient medical history
From the above table, we can see that when propositions are LOW or NO_CANCER,
increasing the mass of the four propositions from 0.3 to 0.7, will lead to an increase in the belief
of not having pancreatic cancer. When the propositions are of high correlation will cause
pancreatic cancer, increasing the mass from 0.3 to 0.7 increases the prediction of probability of
having pancreatic cancer. When the propositions are of MEDIUM or SOME_CANCER, change
in mass doesn’t lead to a change in the prediction. In addition, we can observe that when keeping
mass the same for all four propositions, changing propositions from MEDIUM to HIGH lead to
an increase in the chance of having pancreatic cancer. The results match with expectation.

C. ER Experiment 3
Since there’s an intermediate node created for NOVEL_MUTATION and
PATHWAY_MUTATION. This experiment aims to demonstrate how novel mutation, pathway
mutation affects the result of prediction. Adjust the two frames and keep the values of all other
input parameters the same as the baseline values. The prediction results are shown in the
following table:
Novel mutation

Pathway mutation

Proposition

Mass

Proposition

Mass

NOT_NOVEL

0.7

LOW_
IMPACT

0.7

17

Belief Of Having
Pancreatic Cancer
Lies Between:

Belief Of Not
Having Pancreatic
Cancer Lies
Between:

(0.09, 0.203)
(0)|***-------|(1)

(0.796, 0.909)
(0)|-------***|(1)
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NOVEL

0.7

LOW_
IMPACT

0.7

(0.089, 0.201)
(0)|***-------|(1)

(0.798, 0.91)
(0)|-------***|(1)

NOT_NOVEL

0.3

MEDIUM_
IMPACT

0.3

(0.09, 0.204)
(0)|***-------|(1)

(0.795, 0.909)
(0)|-------***|(1)

NOT_NOVEL

0.7

MEDIUM_
IMPACT

0.7

(0.09, 0.202)
(0)|***-------|(1)

(0.797, 0.909)
(0)|-------***|(1)

NOVEL

0.7

MEDIUM_
IMPACT

0.7

(0.09, 0.203)
(0)|***-------|(1)

(0.796, 0.909)
(0)|-------***|(1)

NOT_NOVEL

0.7

HIGH_
IMPACT

0.7

(0.089, 0.205)
(0)|***-------|(1)

(0.794, 0.91)
(0)|-------***|(1)

NOVEL

0.7

HIGH_
IMPACT

0.7

(0.09, 0.202)
(0)|***-------|(1)

(0.797, 0.909)
(0)|-------***|(1)

Table 3. Prediction result of various input parameters for novel mutation and pathway mutation
Compared to the baseline prediction when propositions are NOT_NOVEL and
LOW_IMPACT with both masses being 0.5, increasing mass to 0,7 caused a slight increase in
the belief of not having pancreatic cancer. But in general not much variation is observed across
all predictions, this is because there’s not much variation in the compatrel relationships of the
intermediate frame BIO_LOC_X_AMT. MEDIUM_IMPACT or HIGH_IMPACT pathway
mutation could both lead to pancreatic cancer. Mutation being NOVEL or NOT_NOVEL could
both lead to pancreatic cancer.

D. ER Experiment 4
Since there’s an intermediate node created for DNA_METHYLATION,
cfDNA_METHYLATION and mRNA_EXPRESSION. The proposition of cfDNA methylation
is always (LOW_IMPACT, MEDIUM_IMPACT, HIGH_IMPACT) is always 1.0 (Check
Appendix F for more details). This experiment aims to demonstrate how changes in DNA
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methylation, mRNA expression affects the result of prediction. Adjust the three frames and keep
the values of all other input parameters the same as the baseline values. The prediction results are
shown in the following table:
DNA methylation

mRNA expression

Belief Of Having
Pancreatic Cancer
Lies Between:

Belief Of Not
Having Pancreatic
Cancer Lies
Between:

Proposition

Mass

Proposition

Mass

LOW_
IMPACT

0.3

LOW_
IMPACT

0.3

(0.09, 0.204)
(0)|***-------|(1)

(0.795, 0.909)
(0)|-------***|(1)

LOW_
IMPACT

0.7

LOW_
IMPACT

0.7

(0.09, 0.203)
(0)|***-------|(1)

(0.796, 0.909)
(0)|-------***|(1)

MEDIUM_
IMPACT

0.3

MEDIUM_
IMPACT

0.3

(0.101, 0.213)
(0)|-**-------|(1)

(0.786, 0.898)
(0)|-------**-|(1)

MEDIUM_
IMPACT

0.7

MEDIUM_
IMPACT

0.7

(0.167, 0.273)
(0)|-**-------|(1)

(0.727, 0.832)
(0)|-------**-|(1)

HIGH_
IMPACT

0.3

HIGH_
IMPACT

0.3

(0.101, 0.213)
(0)|-**-------|(1)

(0.786, 0.898)
(0)|-------**-|(1)

HIGH_
IMPACT

0.7

HIGH_
IMPACT

0.7

(0.166, 0.273)
(0)|-**-------|(1)

(0.727, 0.833)
(0)|-------**-|(1)

Table 4. Prediction result of various input parameters for DNA methylation, cfDNA methylation,
and RNA expression.
When the propositions are of LOW_IMPACT, an increase in the mass from 0.3 to 0.7
doesn’t lead to much change in the belief of not having pancreatic cancer. When the proposition
is of MEDIUM_IMPACT or HIGH_IMPACT, an increase in the mass from 0.3 to 0.7 will cause
an increase in the belief of having pancreatic cancer. The belief of having pancreatic cancer is
higher when the proposition is HIGH_IMPACT or MEDIUM_IMPACT, compared to when the
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proposition is LOW_IMPACT. The prediction doesn’t change much when changes made from
MEDIUM_IMPACT to HIGH_IMPACT.

E. ER Experiment 5
Circulating Tumor Cells (CTC) is a new biomarker frame added to the ER model with no
intermediate nodes between other frames. This experiment demonstrates how adjusting this
frame affects the final result when keeping other values the same. Set CTC to the following
parameters and run the program:
CTC

Belief Of Having
Pancreatic Cancer
Lies Between:

Belief Of Not Having
Pancreatic Cancer
Lies Between:

Proposition

Mass

LOW

0.3

(0.203, 0.349)
(0)|--**------|(1)

(0.65, 0.796)
(0)|------**--|(1)

LOW

0.7

(0.114, 0.198)
(0)|-*--------|(1)

(0.801, 0.886)
(0)|--------*-|(1)

MEDIUM

0.3

(0.363, 0.522)
(0)|---***----|(1)

(0.477, 0.637)
(0)|----***---|(1)

MEDIUM

0.7

(0.578, 0.684)
(0)|-----**---|(1)

(0.315, 0.422)
(0)|---**-----|(1)

HIGH

0.3

(0.361, 0.52)
(0)|---***----|(1)

(0.479, 0.639)
(0)|----***---|(1)

HIGH

0.7

(0.577, 0.684)
(0)|-----**---|(1)

(0.315, 0.423)
(0)|---**-----|(1)

Table 5. Prediction result of various input parameters for CTC.
When the proposition is of LOW, an increase in the mass from 0.3 to 0.7 will cause an
increase in the belief of not having pancreatic cancer. When the proposition is of MEDIUM or
HIGH, an increase in the mass from 0.3 to 0.7 will cause an increase in the belief of having
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pancreatic cancer. The belief of having pancreatic cancer is higher when the proposition is HIGH
or MEDIUM, compared to when the proposition is LOW. The prediction doesn’t change much
when changes made from MEDIUM to HIGH.

F. ER Experiment 6
CNV is a new biomarker frame added to the ER model with no intermediate nodes
between other frames. This experiment demonstrates how adjusting this frame affects the final
result when keeping other values the same. Set CNV to the following parameters and run the
program:
CNV

Belief Of Having
Pancreatic Cancer
Lies Between:

Belief Of Not Having
Pancreatic Cancer
Lies Between:

Proposition

Mass

LOW_IMPACT

0.3

(0.643, 0.72)
(0)|------**--|(1)

(0.28, 0.356)
(0)|--**------|(1)

LOW_IMPACT

0.7

(0.578, 0.649)
(0)|-----**---|(1)

(0.351, 0.421)
(0)|---**-----|(1)

MEDIUM_IMPACT

0.3

(0.679, 0.76)
(0)|------**--|(1)

(0.24, 0.32)
(0)|--**------|(1)

MEDIUM_IMPACT

0.7

(0.678, 0.761)
(0)|------**--|(1)

(0.239, 0.321)
(0)|--**------|(1)

HIGH_IMPACT

0.3

(0.716, 0.787)
(0)|-------*--|(1)

(0.212, 0.284)
(0)|--*-------|(1)

HIGH_IMPACT

0.7

(0.771, 0.829)
(0)|-------**-|(1)

(0.17, 0.228)
(0)|-**-------|(1)

Table 6. Prediction result of various input parameters for CNV.
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When the proposition is of LOW_IMPACT, an increase in the mass from 0.3 to 0.7 will
cause an increase in the belief of not having pancreatic cancer. When the proposition is of
MEDIUM_IMPACT, the prediction remains the same as the mass changes. When the
proposition is of HIGH_IMPACT, an increase in the mass from 0.3 to 0.7 will cause an increase
in the belief of having pancreatic cancer. The belief of having pancreatic cancer increases when
the impact of proposition increases when keeping the mass the same.

V. CONCLUSION AND ANALYSIS
Overall, the outcome of ER prediction matches with expectation, that increase in the
mass of a proposition, doesn’t change the direction of prediction, but will increase the belief in
the prediction. Sometimes changes in the proposition do not cause change in the prediction. This
is because the different combination of the compateral relationship could lead to the same
prediction in the galley definition. The hyperparameters can be fine tuned by assigning a frame
continuous proposition type and may create more variation in the compateral relationships. It is
observed that variation in frames that do not connect to intermediate nodes create a greater
impact in the magnitude in the prediction, compared to those connected to intermediate frames.
This may be caused by modulation in the intermediate frames which reduce the impact of
changes.
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VI. FUTURE WORK
Some other prognostic factors that lead to pancreatic cancer could also be added to the
current model. Studies of proteomics, metabolomics have revealed certain proteins and miRNA
can be potential biomarkers for detecting pancreatic cancer. Other factors including dietary
habits, allergies, and some ecological factors may also lead to a higher chance of getting
pancreatic cancer, which hasn’t been considered in our project. Secondly, the genomic data of
this project is gathered from The Cancer Genome Atlas Program (TCGA), which only has 185
cases in the pancreatic adenocarcinoma project. This creates an imbalance in the dataset, as
pancreatic cancer cases are only a small portion in the whole dataset [22]. Therefore, more data
for pancreatic cancer data is desired. Due to COVID-19 social distancing restrictions, our project
is not able to sequence real pancreatic cancer tissue from the California State University (CSU)
East Bay lab. In the future, the credibility of this ER model could be further validated if genomic
data from real tumor samples could be used. Moreover, since the discount value decreases the
credibility of each input frame in prediction, more research needs to be done to justify if the
discount values are appropriate. In addition, there are so many different combinations of
propositions and masses of different frames. From the experiments we can observe that some
frames have greater impacts on the magnitude of prediction than others. More parameter tuning
needs to be done to find the desired mass for each frame, or even for each proposition. More in
depth research may help to find the data to back up the mass value assigned to each frame.The
next phase of this project should also collect genomic data for testing each biomarker to verify if
the prediction is correct.
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APPENDIX A
Frames

Assigned Proposition

Support

ML_PREDICTION

NOT_PC

0.5

NGS_TECH

ionTorrent

0.5

SEQ_READ

LOW_GC_x_LOW_HMR

0.5

SMOKING_HISTORY

LOW

0.5

DRINKING_HISTORY

LOW

0.5

FAMILY_MED_HISTORY

NO_CANCER

0.5

PATIENT_MED_HISTORY

NO_CANCER

0.5

BIOPSY_SITE_CELL_RESULT

NOT_NEAR_PAN_IRREG

0.5

AMOUNT_GEN_MATERIAL

SMALL

0.5

NOVEL_MUTATION

NOT_NOVEL

0.5

PATHWAY_MUTATION

LOW_IMPACT

0.5

DNA_METHYLATION

LOW_IMPACT

0.5

cfDNA_METHYLATION

(LOW_IMPACT,
MEDIUM_IMPACT,
HIGH_IMPACT)

1.0

mRNA_EXPRESSION

LOW_IMPACT

0.5

EXOSOME_MiRNA

LOW_IMPACT

0.5

CNV

LOW_IMPACT

0.5

CTC

LOW

0.5

Table 7. Baseline Propositions and Corresponding Support
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APPENDIX B
Frames

Discount Rate

ML_PREDICTION

0.1

NGS_TECH

0.2

SEQ_READ

0.1

NGS_X_SEQ_READ

0.1

SMOKING_HISTORY

0.3

DRINKING_HISTORY

0.3

FAMILY_MED_HISTORY

0.2

PATIENT_MED_HISTORY

0.1

BIOPSY_SITE_CELL_RESULT

0.2

AMOUNT_GEN_MATERIAL

0.1

NOVEL_MUTATION

0.3

PATHWAY_MUTATION

0.1

DNA_METHYLATION

0.2

cfDNA_METHYLATION

0.1

mRNA_EXPRESSION

0.2

EXOSOME_MiRNA

0.1

CNV

0.5

CTC

0.1

Table 8. Discount Rates and Corresponding Frames
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APPENDIX C
Novel Mutation
There are more and more discoveries of novel mutations that would increase the chance
of developing pancreatic cancer. [25] describes one of the largest whole-genome association
studies, where more than 11.3 million variants were analyzed in more than 21,536 persons.
Among these genetic donors, 9,040 are pancreatic cancer patients and 12,946 are healthy
individuals of European descent. It involved researchers from the National Cancer Institute,
Johns Hopkins Kimmel Cancer Center and other collaborators from over 80 other worldwide
institutions.
From the study, five novel genetic changes were identified to have linkage to increasing
pancreatic cancer risk. Commenting on this study, Alison Klein, a professor of oncology,
pathology and epidemiology, highlighted that a holistic consideration of all five variants is vital
in understanding pancreatic cancer development. On an individual basis, though these variants
can result in modest changes, they aren't sufficient as indicators of pancreatic cancer detection.
These variants are located on the human chromosomes 1, 7, 8, 17. One of the variants
was found in a protein-coding gene, NOC2L, which binds directly to gene p53, which drives
pancreatic cancer development. This then binds with another variant, a tumor gene, p63, that's
associated with increased pancreatic cancer risk.
The third variant was identified in the HNF4G and HNF1B genes, they are growth factors
that regulate cell growth. The next variant was found near the GRP gene, which is associated
with the regulation of gastrointestinal hormones. And the final variant was found on the TNS3
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gene, which possibly aids metastasis. According to the study leader, Alison Klein, PH.D.,
M.H.S., changes of these five identified regions increases the risk of getting pancreatic cancer
but yet, there's still a whole lot more to learn about hereditary factors associated with high-risk
patients.
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Appendix D
Pathway mutation
Pancreatic cancer genomes are characterized by several genetic mutations which aid the
development and progression of neoplastic lesions. Driver mutations such as K-Ras, initiate the
disease development while passenger mutations like phosphoinositide-3-kinase (PI3K),
CDKN2A and ERBB2, amplify its progression.
PDAC are genetically heterogeneous tumors of which K-Ras are the first detected major
driver mutations during progression in over 90% of patients, constituting the most frequently
mutated oncoprotein [26]. Mutated K-Ras activates several downstream effector-signalling
pathways like PI3K, which are linked with migration, proliferation and metastasis. In PDAC
patients, the most common K-Ras mutation points are G12D and G12V.
As for PI3K signalling pathway, studies have indicated that they inhibit cellular apoptosis
and stimulate the proliferation of cancerous cells. An estimate of about 60% of PDAC patients
have a deregulated PI3K/Akt signalling pathway [27]. There are three classes of PI3Ks, grouped
as Class I, Class II and Class III. And studies have indicated that the Class I PI3K are more
responsible for the proliferation of pancreatic cancers. It modulates downstream signalling
cascades in response to stimuli from several growth factor receptors on the cancerous cell surface
[27].
Also, serine-threonine kinase (Akt) functions as regulators of diverse cellular processes
that are very vital for cell growth. Development of a screening methodology that's highly
sensitive in analyzing the high incidences of mutations in the PI3K signalling pathway will aid
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the early detection of pancreatic cancers. Also, asides from early detection, understanding
thoroughly these signalling pathways can aid to improve the therapeutic options available.

29

THE USE OF EVIDENTIAL REASONING MODEL WITH BIOMARKERS IN PANCREATIC CANCER PREDICTION

Appendix E
DNA methylation
DNA methylation is a biological process that occurs when methyl group bonds with the
carbon 5 of cytosines from a DNA molecule, to form 5-methylcytosine (5mC), due to a DNA
methyltransferases mediated covalent addition [28].
DNA methylation is vital in the progression of cancers. When found at the regulatory
regions of a gene, it results in the transcription of such a gene being suppressed. It alters the
chromatin structure and silences the tumor suppressor gene or activates oncogenes.
The use of DNA methylation analysis promises to be effective because cfDNA are more
informative, sensitive and carries methylation markers that makes it easier to identify
tissue-specific cell death. It is interesting to note that DNA methylation profiles appear very
similar when originating from the same tissue. So scientists are able to decipher the
heterogeneous signals emanating from a cfDNA pool to locate the originating tissues [29].
Some notable methods used in the assessment of DNA methylation include
Methylation-specific PCR (MSP), Quantitative Methylation Specific PCR (QMSP), Targeted
Amplicon Sequencing, and a whole lot of others [30]. A large number of these methods are
dependent on the relatively fast deamination of unmethylated cytosines into uracils [28]. A
recent study [30] of the methylation profile of genes ADAMTS1 and BNC1, found the promoter
methylation of the two genes could be vital biomarkers for the early detection of pancreatic
cancer.
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Appendix F
Cell-free DNA/cfDNA methylation
In carrying out screening for pancreatic cancers, the analysis of pancreatic juice can
provide more information when compared to other forms of analysis. But it is a more
cumbersome and invasive means of obtaining specimen samples. This has led to the exploration
of other sensitive and non-invasive methods for early detection.
Right now one worthy approach involves the study of circulating cell-free DNA
(cfDNA), which are carriers of specific markers that help to identify certain cell death. cfDNA
refers to degraded DNA fragments that are released into the blood plasma. It is made up of short
double-stranded segments of nucleic acids. Analysis of cfDNA presents a minimally
non-invasive approach as they are present as polynucleotide chains of 0.1-20 kilobase-base pairs
in the plasma and serum [29].
Increased levels of cfDNA in the plasma can be as a result of stroke, trauma or even
strenuous exercises, but its concentration can't be compared to those of a cancer patient. While a
healthy individual's cfDNA concentration can range from 0 to 100 ng/ml of blood, a cancerous
patient presents an average of 4 to 40 times increased levels [29]. So invariably, the higher the
plasmatic cfDNA levels observed, the higher the cancer's cellular turnover. cfDNA are carriers
of markers for KRAS and DNA methylation signatures. Once cfDNA is sequenced, the genetic
information of a tumor becomes available since all tumors exhibit genetic alterations.
A major hurdle encountered with the circulating cfDNA is that certain factors limit the
information provided by the genetic sequence. Together, factors such as heterogeneous genetic
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background, inter-individual variability of plasmatic levels and having diverse origin from both
healthy and neoplastic cells, makes the interpretation of its sequence data cumbersome.
Nevertheless, analyzing the sequence data obtained from the circulating cfDNA is a method that
holds a lot of promise in the prior diagnosis of pancreatic cancer.
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Appendix G
mRNA-expression
In addition to DNAs, protein-coding mRNAs from the tumor tissues are released into the
blood, and can reflect changes in tumor specific gene expression. Combined with advances in
molecular diagnostics, systematic profiling of cell free m-RNA can improve our understanding
of cancer pathology and identify novel biomarkers for early detection, without the need for
invasive biopsy.
Certain cell-free m-RNA species are in complexed forms that protect them from
degradation by RNases [31]. This ensures their stability in the circulation, in contrast to
complex-free RNA, which is rapidly degraded. Therefore, key challenges in the cell free m-RNA
testing include its extremely low abundance, susceptible to degradation, relatively unstable and
poor extraction efficiency. Circulating cell free m-RNA carries information from human tissues;
the pattern of cell free m-RNA expression reflects cancer cell growth and reproduction,
dysfunction of cancer immunity, which makes cell free m-RNA expression signature a promising
biomarker for early diagnostic, prognostic and therapeutic purposes [32].
While several research reports have shown impressive promises of circulating cell free
m-RNA, there’s still a lot more need to be learned in this field. The advantage of using
circulating cell free m-RNA is that, compared to protein biomarkers, PCR can be used in
detecting circulating cell free m-RNA at a single molecule level [33].
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Appendix H
Exosomes-miRNA
Exosomes are membrane-bound extracellular vesicles that are generated by the
endosomal compartment, functioning as prominent mediators of intercellular communication
[34]. So, through the transfer of biological materials, they instruct, regulate and re-educate their
microenvironment and target organs. Some of the components of exosomes include lipids,
proteins and nucleic acids such as DNA, microRNA (miRNA) and so on. Analysis of exosomes
offers a minimally invasive or non-invasive method because they are easily isolated and
identified in body fluids.
For early detection, exosome-microRNA holds a lot of potential as an effective
biomarker. miRNA is a small non-coding RNA molecule of about 19-25 nucleotides, invariably
regulating gene expression in almost all cellular processes, including carcinogenesis [34]. Their
dysfunction often results in the initiation, growth and spread of cancer.
The signature profile of a pancreatic cancer's miRNA is very different when compared
with that of a normal pancreatic cell. And they tend to be upregulated in patients diagnosed of
having pancreatic cancers than those with benign pancreatic disorders. So when achieved, an
exosomal miRNA-based detection can aid in early detection of dysfunctional miRNA at its
localized stage, using a minimally invasive or non-invasive method.
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Appendix I
CTC
Circulating tumor cells(CTC) refers to detached cells emanating from a primary tumor that's in
circulation in the bloodstream. CTCs are capable of metastasizing in distant organs as offshoots
of their primary tumor. Invariably, this means that CTCs tend to be upregulated as the disease
progresses, serving as an indicator for cancer progression.
Although, due to metastatic inefficiency, only an estimated 0.01% of CTCs progresses to
form metastases, accounting for its rarity in per millimetre of blood [35]. Still yet,
notwithstanding the fact that it can't exclusively indicate clinically significant macro-metastases,
it certainly indicates the presence of malignant tumors which can aid in the early prognosis of
pancreatic cancer.
As a result of their low frequency in per milliliter of blood, detection and isolation are
quite difficult. Thus, it employs a two-step procedure for isolation:
Step1. CTC Enrichment: CTC enrichment technique isolates CTCs based on either
through their surface antibody or their electric charge or cell size. CellSearch is an example of a
surface antibody-based technique. Referred to as the "gold standard" by authors, it is the only
method that's approved by the FDA for diagnosis of breast, colorectal and prostate cancers [36].
Step 2. CTC Detection: The detection of enriched CTCs is carried out either through
morphological examination, mRNA analysis or mutational analysis of the DNA.
Some technologies developed for CTC isolation include ScreenCell, ISET, ApoStream,
ClearCell FX System and so on.
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Appendix J
CNV
Copy number variation (CNV) refers to an occurrence where sections of a genome are
repeated, and between individuals, there's a variation of the number of repeats in the genome
[23]. They are vital in displaying variations within a population, modulating gene expression and
even disease phenotype. In pancreatic cancer, several genes have been differentially expressed
due to copy number alterations. Familial pancreatic cancers are as a result of heritable alterations
in at least a rare major gene.
In the structural architecture of copy number variations, researchers have identified
hotspot regions where copy number variations are more enriched in a genome. In these regions,
they have an increased rate of chromosomal rearrangements that's also responsible for genetic
diseases. These CNV hotspots are consistent in many populations regardless of your
ethnographic origin [23].
For example, analyzing the CNV of mutations in the PRSS1 gene can assist in identifying
high-risk patients regardless of the ethnographic origin [37]. Developing a screening
methodology that'll identify the CNV hotspot regions for pancreatic cancers will greatly aid the
early detection of pancreatic cancers.
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Appendix K
The program for this project is written in Python. Values for mass, discount and
propositions can be defined and modified for a particular frame to test how the changes affect the
final prediction. Values for propositions and masses for different frames are defined in
md_input.txt. Discount values for various frames are defined in the pc_discount_rates.py. Code
in update_md_input.py serves to automate the process of adjusting the mass and proposition
values for different frames. The program reads definition from md_input_uddate.txt to update the
values in md_input.txt. In md_input_uddate.txt, an initial mass value, mass increment rule, and a
list of propositions can be provided for different frames. The automate updating program reads
the list of propositions for each frame, and updates the mass for each proposition based on mass
increment rule starting from the initial mass. For example, if for the frame
DRINKING_HISTORY, the list of propositions given are {(LOW), (MEDIUM), (HIGH)} with
initial mass 0.2, and mass updating rule is +0.2, then the program will automatically update the
values for the frame DRINKING_HISTORY in md_input.txt, starting from proposition LOW
with mass 0.2, then increase mass to 0.4, and keeping increment mass as long as its <= 1.0. After
that, the program will use the next proposition MEDIUM in the list with the initial mass 0.2, and
repeat the process to update mass, and this process will be repeated for proposition HIGH as
well. After each update, the program will also run the evidential reasoning program
predict_pac_new.py, which reads input parameters from md_input.txt to make predictions and
record the input mass, propositions for the updated frame along with the outcomes in result.txt.
If multiple frames are defined in md_input_uddate.txt, the updating program will update
each frame just like the above example in md_input.txt simultaneously, and record outcomes in
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result.txt. Mass updating rule can be set as incrementing using “+” sign or decrementing with “-”
sign in front of the numeric value, if the initial mass is 0.7, and mass update rules is -0.2, then for
each update, the program will decreatement mass for each proposition till >= 0.0. When defining
propositions to be updated for each frame, each proposition should be surrounded by a pair of
and separated by a space.
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